|
Jan 3
|
Clene's Phase 2 REPAIR-PD and REPAIR-MD Trials Support Advancement to Phase 3
|
|
Dec 22
|
Clene Announces New Data from HEALEY ALS Platform Trial
|
|
Dec 21
|
Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension
|
|
Dec 21
|
Clene Provides Update on ALS Clinical Development Meeting With FDA
|
|
Dec 19
|
How Clene CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders
|
|
Dec 8
|
Nobel Prize in Chemistry's Spotlight on Nanotechnology Shines Light on Clene Efforts to Develop Catalytically Active Nanoparticles
|
|
Nov 15
|
Insider Spends US$103k Buying More Shares In Clene
|
|
Nov 14
|
Clene Among Grant Awardees Selected to Advance Scientific Research on ALS
|
|
Nov 9
|
Clene Announces Q3 2023 Financial Results, Operating Highlights
|
|
Nov 7
|
Clene Inc (CLNN) Reports Q3 2023 Financial Results: Significant Survival Benefits and $45. ...
|
|
Nov 7
|
Clene Reports Third Quarter 2023 Financial Results and Operating Highlights
|
|
Oct 31
|
Clene Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up Analysis
|
|
Oct 5
|
National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS
|
|
Sep 29
|
Clene Investigational Drug Focus of Study Published in Peer-Reviewed Journal
|
|
Apr 25
|
ALS and MS Clinical Data from Clene’s CNM-Au8® Featured in Multiple Presentations at the 2023 American Academy of Neurology Annual Meeting
|